Weekly Investment Analysts’ Ratings Updates for Incyte (INCY)

A number of firms have modified their ratings and price targets on shares of Incyte (NASDAQ: INCY) recently:

• 8/20/2026 – Incyte had its “buy” rating reaffirmed by Benchmark Co..
• 8/20/2026 – Incyte is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $152.00 price target on the stock.
• 8/20/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $150.00 price target on the stock.
• 8/17/2026 – Incyte had its price target raised by Piper Sandler from $110.00 to $130.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – Incyte had its “market perform” rating reaffirmed by Sanford C. Bernstein. They now have a $104.00 price target on the stock.
• 8/4/2026 – Incyte had its price target raised by Mizuho from $121.00 to $137.00. They now have an “outperform” rating on the stock.
• 8/3/2026 – Incyte had its “buy” rating reaffirmed by Citigroup Inc..
• 8/3/2026 – Incyte had its price target raised by Leerink Partners from $131.00 to $155.00. They now have an “outperform” rating on the stock.
• 8/1/2026 – Incyte was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/29/2026 – Incyte was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 7/29/2026 – Incyte had its price target raised by Royal Bank Of Canada from $99.00 to $109.00. They now have a “sector perform” rating on the stock.
• 7/29/2026 – Incyte had its price target raised by Guggenheim from $136.00 to $150.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Incyte was given a new $119.00 price target by Morgan Stanley.
• 7/29/2026 – Incyte had its price target raised by Barclays PLC from $134.00 to $139.00. They now have an “overweight” rating on the stock.
• 7/29/2026 – Incyte had its price target raised by BMO Capital Markets from $112.00 to $130.00. They now have a “market perform” rating on the stock.
• 7/29/2026 – Incyte had its price target raised by HC Wainwright from $140.00 to $150.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Incyte was given a new $145.00 price target by Stifel Nicolaus.
• 7/28/2026 – Incyte had its “market perform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $120.00 price target on the stock.
• 7/23/2026 – Incyte had its price target raised by Morgan Stanley from $103.00 to $104.00. They now have an “equal weight” rating on the stock.
• 7/23/2026 – Incyte had its price target raised by JPMorgan Chase & Co. from $105.00 to $110.00. They now have a “neutral” rating on the stock.
• 7/21/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $140.00 price target on the stock.
• 7/15/2026 – Incyte had its “market perform” rating reaffirmed by Citigroup Inc..
• 7/14/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright.
• 7/14/2026 – Incyte had its price target raised by Barclays PLC from $117.00 to $134.00. They now have an “overweight” rating on the stock.
• 7/13/2026 – Incyte had its price target raised by BMO Capital Markets from $94.00 to $112.00. They now have a “market perform” rating on the stock.
• 7/7/2026 – Incyte had its price target raised by Royal Bank Of Canada from $95.00 to $99.00. They now have a “sector perform” rating on the stock.
• 6/29/2026 – Incyte had its “buy (b-)” rating reaffirmed by Weiss Ratings.
• 6/26/2026 – Incyte had its price target raised by UBS Group AG from $103.00 to $113.00. They now have a “neutral” rating on the stock.

Insiders Place Their Bets

In related news, insider Pablo J. Cagnoni sold 10,801 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total value of $1,356,173.56. Following the transaction, the insider directly owned 183,200 shares in the company, valued at $23,002,592. This trade represents a 5.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrick A. Mayes sold 41,899 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $119.46, for a total transaction of $5,005,254.54. Following the transaction, the executive vice president owned 61,441 shares in the company, valued at approximately $7,339,741.86. The trade was a 40.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 16.20% of the company’s stock.

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.